Recruiting

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity. The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the…

ClinicalTrials.gov IDNCT05114096

PhasePHASE4

Enrollment3254

SponsorMcMaster University

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Preterm Birth, Premature Birth, Complication of Prematurity, Obstetric Labor, Premature, Pregnancy Complications

About this study

Interventions

Drug: Celestone + placebo — After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
Drug: Celestone + Celestone — After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.

Primary outcomes

Perinatal Mortality or Substantial Neonatal Morbidity (approximately 1 month)

Eligibility information

Inclusion Criteria: 1. Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and \<34 weeks and 6 days gestation who have received only a single dose of Celestone within 24 hours 2. Capable of giving informed, written consent. Exclusion Criteria: 1. Contraindication to corticosteroids 2. Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc). 3. Previous participation in this trial (in a previous pregnancy) 4. Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality) 5. Demise of one or more fetuses after 14 weeks and 0 days

Study locations

University of Calgary, Cumming School of Medicine, Calgary, Alberta Canada
Alberta Health Services; University of Alberta, Edmonton, Alberta Canada
Royal Columbian Hospital, New Westminster, British Columbia Canada
Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery Centre, Surrey, British Columbia Canada
University of British Columbia; BC Women's Hospital, Vancouver, British Columbia Canada
Victoria General Hospital, Victoria, British Columbia Canada
University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba Canada
University of Manitoba; St. Boniface General Hospital, Winnipeg, Manitoba Canada
Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick Canada
The Moncton Hospital, Horizon Health Network, Moncton, New Brunswick Canada

Showing 10 of 25 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.